Is it appropriate to increase gabapentin to 400 mg three times daily for anxiety in a 56‑year‑old male in residential rehabilitation who is already taking amitriptyline, trazodone, melatonin, and hydroxyzine PRN, assuming normal renal function?

Gabapentin 400 mg TID for Anxiety: Proceed with Caution

Increasing gabapentin to 400 mg three times daily (1200 mg/day total) for anxiety in this patient is not an evidence-based approach and carries significant concerns, particularly given his substance use history and polypharmacy. While the dose itself is within FDA-approved ranges for neuropathic pain, gabapentin lacks FDA approval for anxiety disorders and has emerging abuse potential in populations with substance use disorders 1.

Key Clinical Concerns

Lack of Evidence for Anxiety Treatment

Gabapentin is not FDA-approved for anxiety disorders 1. The available evidence consists primarily of:

• Small case reports and open-label studies 2, 3, 4
• One small study (n=32) showing modest anxiolytic effects at 800 mg single doses in simulated public speaking 5
• No randomized controlled trials for generalized anxiety disorder 2

Recent expert consensus explicitly recommends caution with gabapentinoids in psychiatric practice 6, and newer algorithms for anxiety in older adults list gabapentin/pregabalin only as third-line options after SSRIs, SNRIs, and buspirone 7.

Substance Abuse Risk

This is the most critical concern. Gabapentin has documented abuse potential, particularly in individuals with substance use disorders 8, 6. The 2019 AGS Beers Criteria specifically warns about concurrent use of opioids with gabapentinoids due to increased CNS depression and overdose risk 8. While this patient isn't on opioids, his active recovery status in a residential rehabilitation program makes gabapentin a particularly risky choice.

Problematic Polypharmacy

The patient is already taking:

• Amitriptyline (anticholinergic TCA)
• Trazodone (sedating antidepressant)
• Hydroxyzine PRN (sedating antihistamine)
• Melatonin

Adding gabapentin creates a dangerous combination of CNS depressants 8. The AGS Beers Criteria explicitly warns against concurrent use of three or more CNS-active agents (antidepressants, benzodiazepines, antiepileptics, etc.) due to increased fall risk 8. This patient would have at least four sedating medications.

The anticholinergic burden is also concerning—amitriptyline already carries significant anticholinergic load, and adding gabapentin's sedative effects compounds cognitive impairment risk 9.

Evidence-Based Alternatives

First-Line Approach: Optimize Current Medications

Before adding gabapentin, optimize the amitriptyline dose for anxiety and depression. TCAs like amitriptyline have established efficacy for both conditions 10. The current dose isn't specified, but therapeutic ranges for anxiety/depression typically reach 75-150 mg/day 11. Given his age (56), obtain a screening ECG and monitor for cardiac effects 11.

Second-Line: Consider SSRI/SNRI

If amitriptyline optimization fails or isn't tolerated, switch to an SSRI (sertraline or escitalopram preferred) or SNRI (duloxetine or venlafaxine) 12, 7. These have:

• FDA approval for anxiety disorders
• Established efficacy in bereavement-related depression
• Better safety profiles than gabapentin in substance use populations

Duloxetine specifically has FDA approval for generalized anxiety disorder and requires simple dosing (30 mg daily for 1 week, then 60 mg daily) 11.

Third-Line: Buspirone

For a relatively healthy 56-year-old, buspirone (starting 5 mg BID, titrating to 20 mg TID) is a safer anxiolytic than gabapentin 10, 7. It lacks abuse potential and doesn't add to CNS depression, though it requires 2-4 weeks for effect 10.

If Gabapentin Must Be Used

Should you proceed despite these concerns:

1. Start lower than planned: Begin at 100-300 mg at bedtime, not 400 mg TID 11, 1
2. Titrate slowly: Increase by 100-300 mg every 1-7 days as tolerated 11
3. Monitor closely for:
   • Sedation and cognitive impairment (dose-dependent) 11
   • Signs of misuse/diversion
   • Falls risk (especially with concurrent sedating medications)
4. Verify normal renal function before each dose increase 11, 1
5. Coordinate with substance use treatment team regarding abuse monitoring

Critical Pitfalls to Avoid

• Don't assume gabapentin is "safer" than benzodiazepines in substance use populations—it has its own abuse liability 8, 6
• Don't ignore the polypharmacy burden—morning grogginess on trazodone suggests he's already experiencing CNS depression 8
• Don't use gabapentin as first-line for anxiety—evidence-based treatments exist 12, 7
• Don't forget that bereavement and situational stressors may respond better to psychotherapy than medication escalation

The better clinical approach is to optimize evidence-based treatments (amitriptyline dose adjustment or switch to SSRI/SNRI) while intensifying psychotherapeutic support for his grief and housing concerns, rather than adding a fourth CNS depressant with questionable efficacy for anxiety.